ABSTRACT
An evaluation of the therapeutic efficacy of Amisulpride as compared with Viloxazine in a group of patients diagnosed as dysthymic, according to the DSM-III-R criteria is presented. Study was a double-blind, randomized controlled trial: Subjects were assessed during an initial examination with informed consent, then entering a 4-week treatment trial. The Hamilton Depression Scale, the Widlocher Psychomotor Retardation Scale, and the Andreasen Negative Symptoms Scale were used for evaluating cases. Both the efficacy and safety of drugs were assessed. An analysis of results suggests a better therapeutic response among the Amisulpride group subjects.
Subject(s)
Depressive Disorder/drug therapy , Psychotropic Drugs/therapeutic use , Sulpiride/analogs & derivatives , Viloxazine/therapeutic use , Adolescent , Adult , Age Distribution , Amisulpride , Double-Blind Method , Female , Humans , Male , Middle Aged , Psychotropic Drugs/adverse effects , Sex Distribution , Socioeconomic Factors , Sulpiride/adverse effects , Sulpiride/therapeutic use , Viloxazine/adverse effectsABSTRACT
An evaluation of the therapeutic efficacy of Amisulpride as compared with Viloxazine in a group of patients diagnosed as dysthymic, according to the DSM-III-R criteria is presented. Study was a double-blind, randomized controlled trial: Subjects were assessed during an initial examination with informed consent, then entering a 4-week treatment trial. The Hamilton Depression Scale, the Widlocher Psychomotor Retardation Scale, and the Andreasen Negative Symptoms Scale were used for evaluating cases. Both the efficacy and safety of drugs were assessed. An analysis of results suggests a better therapeutic response among the Amisulpride group subjects.
